Patents by Inventor Anchel Schwartz

Anchel Schwartz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selective enzymatic esterification and solvolysis of epimeric vitamin D analog and separation of the epimers
    Patent number: 8129173
    Abstract: Provided is a method of selectively enzymatically esterifying or selectively enzymatically solvolyzing epimers of analogs of vitamin D having a stereogenic center at C-24 that has a free or esterified OH group. The metod can be used, for example, for separating mixed epimers of the vitamin D analog.
    Type: Grant
    Filed: January 9, 2003
    Date of Patent: March 6, 2012
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Evgeny Shapiro, Ayelet Fishman, Reinhard Effenberger, Asher Maymon, Anchel Schwartz
  • Crystallization method for purification of calcipotriene
    Publication number: 20080161587
    Abstract: Provided is a crystallization method for reducing the level of impurities in calcipotriene in which a solution of a starting calcipotriene in a first process solvent, for example THF, is combined with second process solvent, for example methyl formate, and, after cooling, calcipotriene is isolated. The method can include a slurry step for reducing the level of residual first process solvent.
    Type: Application
    Filed: March 7, 2008
    Publication date: July 3, 2008
    Inventors: Anchel Schwartz, Asher Maimon
  • Crystallization method for purification of calcipotriene
    Patent number: 7351869
    Abstract: Provided is a crystallization method for reducing the level of impurities in calcipotriene in which a solution of a starting calcipotriene in a first process solvent, for example THF, is combined with second process solvent, for example methyl formate, and, after cooling, calcipotriene is isolated. The method can include a slurry step for reducing the level of residual first process solvent.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: April 1, 2008
    Assignee: Teva Pharmaceutical Industries Ltd
    Inventors: Anchel Schwartz, Asher Maimon
  • Preparation of paricalcitol
    Publication number: 20070149489
    Abstract: The present invention is directed to a novel process for preparing Paricalcitol wherein Paricalcitol, dissolved in a solvent, is precipitated from a concentrated or seeded solution.
    Type: Application
    Filed: July 18, 2006
    Publication date: June 28, 2007
    Inventors: Anchel Schwartz, Alexei Ploutno, Koby Wolfman
  • Preparation of paricalcitol and crystalline forms thereof
    Publication number: 20070093458
    Abstract: The present invention is directed to a novel process for preparing Paricalcitol wherein Paricalcitol, dissolved in a solvent, is precipitated from a concentrated or seeded solution. The present invention also provides crystalline forms of paricalcitol and processes for their preparations.
    Type: Application
    Filed: September 12, 2006
    Publication date: April 26, 2007
    Inventors: Anchel Schwartz, Alexei Ploutno, Koby Wolfman, Shlomit Wizel
  • Epimerization of analogs of vitamin D
    Patent number: 7205420
    Abstract: Provided is a method of general applicability of epimerizing a vitamin-D analog having an asymmetric allylic carbon atom at the C-24 position. The method is of particular utility in making calcipotriene.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: April 17, 2007
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Evgeny Shapiro, Reinhard Effenberger, Asher Maymon, Anchel Schwartz
  • Crystalline forms of 1,24(S)-dihydroxy vitamin D2
    Publication number: 20060052350
    Abstract: Provided are novel crystalline forms of 1,24-(S)-dihydroxy vitamin D2, including hydrates and solvates, and methods for making them. Also provided are pharmaceutical and nutraceutical compositions containing the novel crystalline forms.
    Type: Application
    Filed: July 1, 2005
    Publication date: March 9, 2006
    Inventors: Alexei Ploutno, Anchel Schwartz, Koby Wolfman, Judith Aronhime
  • Crystallization method for purification of calcipotriene
    Publication number: 20040138184
    Abstract: Provided is a crystallization method for reducing the level of impurities in calcipotriene in which a solution of a starting calcipotriene in a first process solvent, for example THF, is combined with second process solvent, for example methyl formate, and, after cooling, calcipotriene is isolated. The method can include a slurry step for reducing the level of residual first process solvent.
    Type: Application
    Filed: November 18, 2003
    Publication date: July 15, 2004
    Inventors: Anchel Schwartz, Asher Maimon
  • Epimerization of analogs of vitamin D
    Publication number: 20040054204
    Abstract: Provided is a method of general applicability of epimerizing a vitamin-D analog having an asymmetric allylic carbon atom at the C-24 position. The method is of particular utility in making calcipotriene.
    Type: Application
    Filed: June 11, 2003
    Publication date: March 18, 2004
    Inventors: Evgeny Shapiro, Reinhard Effenberger, Asher Maymon, Anchel Schwartz
  • Selective enzymatic esterification and solvolysis of epimeric vitamin D analog and separation of the epimers
    Publication number: 20030166226
    Abstract: Provided is a method of selectively enzymatically esterifying or selectively enzymatically solvolyzing epimers of analogs of vitamin D having a stereogenic center at C-24 that has a free or esterified OH group. The metod can be used, for example, for separating mixed epimers of the vitamin D analog.
    Type: Application
    Filed: January 9, 2003
    Publication date: September 4, 2003
    Inventors: Evgeny Shapiro, Ayelet Fishman, Reinhard Effenberger, Asher Maymon, Anchel Schwartz
  • Torsemide polymorphs
    Patent number: 6465496
    Abstract: The present invention is directed to the novel forms of torsemide, designated Form V, amorphous torsemide, Dupont Form 2 solvent adduct, Dupont Form 2 ethanol adduct and Dupont Form 2 isopropanol adduct. Methods for their preparation are also disclosed. The present invention also relates to processes for making torsemide modification I. Pharmaceutical compositions containing the new forms of torsemide and methods of using them are also disclosed.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: October 15, 2002
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Judith Aronhime, David Leonov, Marko Kordova, Anchel Schwartz, Ben-Zion Dolitzky
  • Micronized torsemide
    Publication number: 20020120147
    Abstract: The present invention relates to torsemide having relatively small particles, and corresponding relatively large surface area. In one embodiment, the invention relates to torsemide and formulations containing torsemide having a mean particle diameter of less than 200 micrometers.
    Type: Application
    Filed: August 14, 2001
    Publication date: August 29, 2002
    Inventors: Marco Kordova, Anchel Schwartz, Ben-Zion Dolitzky, Judith Aronhime, David Leonov, Shlomo Zavurov